The recent approval of CD19-specific CAR-T cell therapy by the FDA has provided a promising treatment for chemotherapy-resistant B-cell non-Hodgkin lymphoma (NHL) and relapsed/refractory pediatric and young-adult diffuse large B-cell lymphoma (DLBCL). Here, CD19 is linked to B-cell non-Hodgkin lymphoma.